Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Folinic acid (Primary) ; Ginisortamab (Primary) ; Fluorouracil; Oxaliplatin; Tipiracil/trifluridine
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Male breast cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors UCB Biopharma

Most Recent Events

  • 30 Apr 2025 Results(n=32) evaluating primary (safety), secondary (pharmacokinetics), and exploratory (biomarker, efficacy) endpoints from Part A1 (monotherapy dose-optimization) presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 02 May 2024 Status changed from active, no longer recruiting to completed.
  • 01 Dec 2023 Planned End Date changed from 13 Feb 2024 to 15 May 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top